NIH Funding Opportunities


NIAID: Impact of Comorbidities and Co-Infections on HIV Reservoirs (R01 Clinical Trial Not Allowed) RFA-DK-25-013

 This Notice of Funding Opportunity (NOFO) seeks to foster new multi-disciplinary teams to address how HIV Comorbidities and co-infections within the missions of NIDDK and NIAID interact with viral reservoirs, potentially confounding cure strategies aimed at either sustained viral suppression or elimination from the body. These teams will mechanistically interrogate the impact of inflammation, metabolic perturbations, or other pathophysiological processes associated with these comorbidities or co-infections on reservoir dynamics, and/or the interplay of these conditions and co-infections on HIV reservoir biology in ways that are likely to interact with potential cure strategies. 

Open Date (Earliest Submission Date): June 30, 2024
Letter of Intent Due Date(s): May 30, 2024
Expiration Date: July 31, 2024


NIAID: Limited Interaction Targeted Epidemiology: Epidemiology of Transmission and Treatment of HIV Among People Who Are at Increased Risk for HIV Infection in Latin America (LITE-LA) (UG3/UH3 Clinical Trial Optional) RFA-AI-24-009

The purpose of this notice of funding opportunity (NOFO) is to support investigators who will form large, electronically-generated cohorts in Latin America of HIV-negative men who have sex with men (MSM), transgender women (TGW), people who inject drugs (PWID), and/or female sex-workers and follow them to study the epidemiology of HIV incidence. Continued follow-up of those persons who acquire HIV will be required to study the epidemiology of viral suppression. Descriptions of these groups and comparisons of participants by seroconversion status will provide information on geographic and socially defined areas of high HIV incidence as well as on both personal and structural vulnerabilities to HIV infection. Studies of participants who seroconvert and comparisons of those becoming rapidly engaged in care and who reach non-detectable HIV levels to those whose virus remains detectable will inform on the treatment of HIV in Latin American countries. This NOFO will allow digital trials to determine optimal study approaches, or to pilot evidence-based digital (mHealth and online) HIV prevention and treatment interventions to both reduce HIV incidence and improve treatment in Latin America.

Open Date (Earliest Submission Date): June 30, 2024
Expiration Date: July 31, 2024


NIAID: Strategies for Controlled Release of HIV Vaccines (SCORE-H) (R01 Clinical Trial Not Allowed)

The purpose of this Notice of Funding Opportunity (NOFO) is to support product-focused research to advance controlled release vaccine strategies to improve immune responses for HIV prevention, treatment, and cure and develop simplified or single-shot vaccination formulations. Timelines with measurable milestones are required. 


Open Date (Earliest Submission Date): June 30, 2024
Expiration Date: July 31, 2024

NIAID: Interaction between ARVs and Hormones in HIV and Coinfections (R01 Clinical Trial Optional)

The purpose of this Notice of Funding Opportunity (NOFO) is to support research to identify and characterize the interaction between hormone therapy and antiretroviral drugs (ARVs) used for treatment and prevention of HIV and co-infections.


Open Date (Earliest Submission Date): June 30, 2024
Expiration Date: July 31, 2024

NIAID - Notice of Special Interest (NOSI): Towards Developing a Cure for HBV in HIV/HBV Co-Infection

The Notice of Special Interest (NOSI) seeks to fill scientific gaps needed to (a) inform HBV cure strategies by furthering our understanding of unique challenges impacting HBV and HIV co-infected hosts; and (b) advance the discovery and development of novel HBV interventions that are safe and achieve a cure in HIV and HBV co-infected individuals.


First Available Due Date: September 05, 2022

Expiration Date: May 08, 2025

NIAID- Notice of Special Interest (NOSI): Sustained Release of Antivirals for Treatment or Prevention of HIV or Treatment of Latent TB/HBV (SRATP)

The purpose of this Notice is to encourage new applications to support further development of a diverse and comprehensive portfolio of SR/LA products for prevention and treatment of HIV. SR/LA antiretroviral products will have a minimum window of protection of three (3) months from either a single dosing (injection, oral administration) or continuous dosing regimen (implant, transdermal patch, etc.) to reflect current state of SR/LA drug market for HIV treatment or prevention.

NOT- AI-22-042

First Available due date: September 7, 2022

Expiration Date: May 8, 2025

At a Glance